These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 19264458)
1. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Tomoda K; Ohkoshi T; Hirota K; Sonavane GS; Nakajima T; Terada H; Komuro M; Kitazato K; Makino K Colloids Surf B Biointerfaces; 2009 Jul; 71(2):177-82. PubMed ID: 19264458 [TBL] [Abstract][Full Text] [Related]
2. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Tomoda K; Ohkoshi T; Nakajima T; Makino K Colloids Surf B Biointerfaces; 2008 Jun; 64(1):70-6. PubMed ID: 18343097 [TBL] [Abstract][Full Text] [Related]
3. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Tomoda K; Ohkoshi T; Kawai Y; Nishiwaki M; Nakajima T; Makino K Colloids Surf B Biointerfaces; 2008 Feb; 61(2):138-44. PubMed ID: 17890065 [TBL] [Abstract][Full Text] [Related]
4. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. Ohashi K; Kabasawa T; Ozeki T; Okada H J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349 [TBL] [Abstract][Full Text] [Related]
5. Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles. Yang M; Yamamoto H; Kurashima H; Takeuchi H; Yokoyama T; Tsujimoto H; Kawashima Y Eur J Pharm Sci; 2012 Aug; 47(1):235-43. PubMed ID: 22683651 [TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Hu L; Jia Y; WenDing Pharmazie; 2010 Aug; 65(8):585-7. PubMed ID: 20824958 [TBL] [Abstract][Full Text] [Related]
7. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150 [TBL] [Abstract][Full Text] [Related]
8. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761 [TBL] [Abstract][Full Text] [Related]
9. Enhanced properties of discrete pulmonary deoxyribonuclease I (DNaseI) loaded PLGA nanoparticles during encapsulation and activity determination. Osman R; Kan PL; Awad G; Mortada N; El-Shamy AE; Alpar O Int J Pharm; 2011 Apr; 408(1-2):257-65. PubMed ID: 21335080 [TBL] [Abstract][Full Text] [Related]
10. Inhalable microspheres embedding chitosan-coated PLGA nanoparticles for 2-methoxyestradiol. Guo X; Zhang X; Ye L; Zhang Y; Ding R; Hao Y; Zhao Y; Zhang Z; Zhang Y J Drug Target; 2014 Jun; 22(5):421-7. PubMed ID: 24417740 [TBL] [Abstract][Full Text] [Related]
11. Drug intercalation in layered double hydroxide clay: application in the development of a nanocomposite film for guided tissue regeneration. Chakraborti M; Jackson JK; Plackett D; Brunette DM; Burt HM Int J Pharm; 2011 Sep; 416(1):305-13. PubMed ID: 21708236 [TBL] [Abstract][Full Text] [Related]
12. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Yang R; Shim WS; Cui FD; Cheng G; Han X; Jin QR; Kim DD; Chung SJ; Shim CK Int J Pharm; 2009 Apr; 371(1-2):142-7. PubMed ID: 19118614 [TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666 [TBL] [Abstract][Full Text] [Related]
14. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. He W; Horn SW; Hussain MD Int J Pharm; 2007 Apr; 334(1-2):173-8. PubMed ID: 17101249 [TBL] [Abstract][Full Text] [Related]
15. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. Roa WH; Azarmi S; Al-Hallak MH; Finlay WH; Magliocco AM; Löbenberg R J Control Release; 2011 Feb; 150(1):49-55. PubMed ID: 21059378 [TBL] [Abstract][Full Text] [Related]
16. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. Mittal G; Sahana DK; Bhardwaj V; Ravi Kumar MN J Control Release; 2007 May; 119(1):77-85. PubMed ID: 17349712 [TBL] [Abstract][Full Text] [Related]
17. [Preparation and characterization of tetrandrine-loaded PLGA nanocomposite particles by premix membrane emulsification coupled with spray-drying method]. Hu T; Zhu HX; Guo LW; Pan LM; Li B; Shi FY; Lu J Yao Xue Xue Bao; 2014 Nov; 49(11):1607-13. PubMed ID: 25757290 [TBL] [Abstract][Full Text] [Related]